ATOSSA THERAPEUTICS, INC. Amortization of Debt Issuance Costs
ATOSSA THERAPEUTICS, INC. (ATOS) reported Amortization of Debt Issuance Costs of $59.56 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2018-11-14
- ATOSSA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2018-09-30 was $19.85K, a 0.00% change year-over-year.
- ATOSSA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2018-06-30 was $19.85K, a 0.01% decline year-over-year.
- ATOSSA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2018-03-31 was $19.85K, a 0.00% change year-over-year.
- ATOSSA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2017-12-31 was $19.85K, a 21.09% increase year-over-year.
- ATOSSA THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2017 was $79.41K, a 85.26% increase from fiscal 2016.
- ATOSSA THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2016 was $42.86K, a 87.95% decline from fiscal 2015.
- ATOSSA THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2015 was $355.71K.
- ATOSSA THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2014 was $0.00.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2018-09-30 | $19.85K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2018-11-14 | $39.70K derived: sum of 2 quarters · filed 2018-11-14 | $59.56K 10-Q · filed 2018-11-14 | $79.41K derived: sum of 4 quarters · filed 2018-11-14 |
| 2018-06-30 | $19.85K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2018-11-13 | $39.70K 10-Q/A · filed 2018-11-13 | $59.55K derived: sum of 3 quarters · filed 2018-11-13 | $79.41K derived: sum of 4 quarters · filed 2018-11-14 |
| 2018-03-31 | $19.85K 10-Q · filed 2018-05-14 | $39.70K derived: sum of 2 quarters · filed 2018-05-14 | $59.56K derived: sum of 3 quarters · filed 2018-11-14 | $79.41K derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-12-31 | $19.85K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $39.70K derived: sum of 2 quarters · filed 2018-11-14 | $59.56K derived: sum of 3 quarters · filed 2018-11-14 | $79.41K 10-K · filed 2018-03-08 |
| 2017-09-30 | $19.85K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2018-11-14 | $39.71K derived: sum of 2 quarters · filed 2018-11-14 | $59.56K 10-Q · filed 2018-11-14 | $75.95K derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-06-30 | $19.85K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2018-11-13 | $39.70K 10-Q/A · filed 2018-11-13 | $56.10K derived: sum of 3 quarters · filed 2018-11-13 | $75.95K derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-03-31 | $19.85K 10-Q · filed 2018-05-14 | $36.25K derived: sum of 2 quarters · filed 2018-05-14 | $56.10K derived: sum of 3 quarters · filed 2018-05-14 | $62.72K derived: sum of 4 quarters · filed 2018-05-14 |
| 2016-12-31 | $16.39K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $36.25K derived: sum of 2 quarters · filed 2018-03-08 | $42.86K derived: sum of 3 quarters · filed 2018-03-08 | $42.86K 10-K · filed 2018-03-08 |
| 2016-09-30 | $19.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $26.47K derived: sum of 2 quarters · filed 2017-11-13 | $26.47K 10-Q · filed 2017-11-13 | -$10.53K derived: sum of 4 quarters · filed 2017-11-13 |
| 2016-06-30 | $6.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $6.62K 10-Q · filed 2017-08-14 | -$30.38K derived: sum of 3 quarters · filed 2017-08-14 | -$30.38K derived: sum of 4 quarters · filed 2017-08-14 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-05 | -$37.00K derived: sum of 2 quarters · filed 2017-03-21 | -$37.00K derived: sum of 3 quarters · filed 2017-03-21 | $3.75K derived: sum of 4 quarters · filed 2017-03-21 |
| 2015-12-31 | -$37.00K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2017-03-21 | -$37.00K derived: sum of 2 quarters · filed 2017-03-21 | $3.75K derived: sum of 3 quarters · filed 2017-03-21 | $355.71K 10-K/A · filed 2017-03-21 |
| 2015-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-03-21 | $40.75K derived: sum of 2 quarters · filed 2017-03-21 | $392.71K 10-Q/A · filed 2017-03-21 | |
| 2015-06-30 | $40.75K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-03-21 | $392.71K 10-Q/A · filed 2017-03-21 | ||
| 2015-03-31 | $351.96K 10-Q/A · filed 2017-03-21 | |||
| 2014-12-31 | $0.00 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |